logo
BP appoints new chair to oversee shift back to fossil fuels

BP appoints new chair to oversee shift back to fossil fuels

The Guardiana day ago
BP has appointed a successor to its embattled chair Helge Lund, as the company breaks from its net zero strategy and pivots back to fossil fuels.
Albert Manifold, the former boss of the building material company CRH, will join the BP board on 1 September as a non-executive director and as chair-elect, before taking over on 1 October.
Lund, chair since 2019 and an important figure in the company's abandoned green push, announced in April he would step down from his position 'most likely during 2026'. Lund also suffered an investor rebellion at BP's AGM amid pressure over its poorly performing share price.
The change in chair comesamid a broader strategic shift at BP, as it cuts back on green spending and returns its focus to oil, after a botched attempt to reinvent itself as a net zero energy company.
Manifold was chief executive of CRH for a decade until the end of last year, and led the shift in the company's primary listing from London to New York in 2023.
The chief executive of BP, Murray Auchincloss, said last year that switching BP's listing to the US was 'not on the agenda'. BP shares have lagged behind its US peers, while a string of British firms have switched their primary listings from London to New York.
Amanda Blanc, the senior independent director at BP who led the process to find a new chair, said Manifold had 'transformed and refocused CRH into a global leader' and praised 'his impressive track record of shareholder value creation'.
Sign up to Business Today
Get set for the working day – we'll point you to all the business news and analysis you need every morning
after newsletter promotion
Manifold, who received a $13m (£9.6m) package for his work at CRH last year, called it 'an honour to be appointed chair of one of the world's great energy companies, and to have the opportunity to help the company reach its full potential'.
BP's green strategy was set by its previous boss Bernard Looney, who was appointed by Lund in 2020 to transform the business into an integrated energy company. However, the transition was undermined by a rise in global oil and gas prices, as well as the shock departure of Looney in 2023.
Auchincloss set out a 'fundamental reset' this year after the activist hedge fund Elliott Management amassed a multibillion-pound stake in the company amid growing investor dissatisfaction over its sluggish share price.
BP has been rapidly scaling back its green portfolio. Last week, it agreed to sell its onshore wind business in the US, as part of a plan to offload $20bn in assets to 'simplify and focus the business'.
Shareshave fallen by more than 10% in the past 12 months, prompting speculation it could become a takeover target. Last month, rival Shell was forced to deny it had any intention of making an offer for BP, which ruled out a formal approach for the next six months.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

French pharma giant swoops on British vaccine champion in $1.6bn deal
French pharma giant swoops on British vaccine champion in $1.6bn deal

Daily Mail​

timea minute ago

  • Daily Mail​

French pharma giant swoops on British vaccine champion in $1.6bn deal

French pharmaceuticals giant Sanofi has agreed to acquire privately-owned British biotech firm, Vicebio, in a deal worth up to $1.6billion (£1.2billion). The deal sees Sanofi take control of Vicebio's early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). London-based Vicebio says it is 'redefining how the world combats respiratory diseases', with its 'Molecular Clamp' tech enabling the development of next-generation vaccines that offer 'broad protection, ready-to-use formulations, and high manufacturability'. Vicebio's vaccine candidate complements Sanofi's existing range, and allows it to offer a wider range to doctors and patients. The French group said on Tuesday it would pay an initial $1.15billion for the London-based respiratory diseases specialist, with a further $450million in milestone payments to be paid based on development and regulatory progress. Sanofi will also gain Vicebio's molecular clamp tech, which is used to help an immune system to recognise and respond to viral proteins more quickly. The acquisition is expected to close in the fourth quarter of 2025. Sanofi says it won't have a significant impact on its 2025 financial guidance. Jean-François Toussaint, global head of research and development vaccines at Sanofi, said: 'Vicebio's Molecular Clamp technology introduces a purposefully simple but thoughtful approach to further improve vaccine designs at a time when respiratory viral infections continue to impact millions globally. 'This acquisition furthers Sanofi's dedication to vaccine innovation with the potential to develop next-generation combination vaccines that could provide protection to older adults against multiple respiratory viruses with a single immunisation.' The acquisition follows a number of recent purchases by Sanofi, following Vigil Neuroscience in May and the DR-0201 cell engager from Dren Bio in March. rMost recently, Sanofi completed its acquisition of Blueprint Medicines last month. Emmanuel Heron, chief executive of Vicebio, said: 'Their global scale and deep expertise in vaccine development provide the ideal environment to fully realize the potential of our innovative technology. 'We look forward to advancing our platform and pipeline to deliver meaningful benefits for patients and public health.'

Gold retreats from five-week high as investors book profits
Gold retreats from five-week high as investors book profits

Reuters

time29 minutes ago

  • Reuters

Gold retreats from five-week high as investors book profits

July 22 (Reuters) - Gold eased on Tuesday as investors booked profits after prices scaled a five-week high, while market participants focussed on trade talks ahead of U.S. President Donald Trump's August 1 deadline. Spot gold fell 0.3% to $3,386.25 per ounce by 0808 GMT. Earlier in the session, bullion hit its highest since June 17. U.S. gold futures were down 0.2% at $3,398.40. Gold prices edged lower amid profit-booking but remained close to the five-week high due to lingering uncertainty ahead of the August 1 tariff deadline, said Jigar Trivedi, a senior commodity analyst at Reliance Securities. "Gold is likely to stay bullish. A strong resistance is seen near $3,420. On the flip side, $3,350 is a support," he said. The U.S. dollar index (.DXY), opens new tab edged up 0.1% against its rivals. A stronger dollar makes greenback-priced gold more expensive for other currency holders. European Union diplomats said the bloc is exploring broader counter-measures against the United States as prospects for a trade agreement with Washington diminish. Trump has threatened 30% tariffs on European imports if no deal is reached before the August 1 deadline. U.S. Treasury Secretary Scott Bessent said the administration prioritises the quality of trade deals over timing. Focus is also on the U.S. Federal Reserve's monetary policy meeting scheduled for next week, where the central bank is expected to hold interest rates steady for now and potentially begin cuts in October. Gold tends to perform well in a low-interest-rate environment and during times of geopolitical and economic uncertainty. Spot silver fell 0.3% to $38.81 per ounce, platinum was steady at $1,437.65 and palladium declined 0.2% to $1,261.93. Russia's Nornickel, the leading global producer of palladium, lowered its palladium output forecast, now expecting between 2.677 and 2.729 million ounces compared with the earlier estimate of 2.704-2.756 million ounces.

Files show Downing Street concern over Blairs' designer clothes deal
Files show Downing Street concern over Blairs' designer clothes deal

The Independent

time31 minutes ago

  • The Independent

Files show Downing Street concern over Blairs' designer clothes deal

Tony Blair was advised by No. 10 officials to repay thousands of pounds in discounts received on designer clothes while prime minister. Newly released official files from the National Archives reveal the recommendation for him to pay back over £7,600 for items from Nicole Farhi and Paul Smith. The significant discounts, up to 60 per cent, were negotiated by Cherie Blair 's style adviser, Carole Caplin, who purchased clothes for both Blairs. Officials expressed concern that such large discounts would not be available to ordinary members of the public and could negatively impact public perception. While Cherie Blair was deemed not to have received preferential treatment, Tony Blair was advised to repay the full amount for his clothes, and future suppliers were to sign confidentiality agreements.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store